Ghrelin as a biomarker of non-motor symptoms  and sleep disorders at Parkinson's disease

doi:10.26565/2617-409X-2022-10-04

Kateryna Tarianyk Poltava State Medical University https://orcid.org/0000-0003-4606-5398
Nataliya Lytvynenko Poltava State Medical University https://orcid.org/0000-0002-4889-3608
Halyna Silenko Poltava State Medical University https://orcid.org/0000-0002-6225-0174
Olena Palenka Poltava State Medical University https://orcid.org/0000-0002-7276-8241

DOI: https://doi.org/10.26565/2617-409X-2022-10-04

Keywords: Parkinson's disease, ghrelin, sleep disorders, non-motor disorders

Abstract

ABSTRACT. Among the movement disorders characterized by Parkinson's disease, an equally important component is non-motor symptoms. To date, the neurophysiological basis of development and potential biomarkers of the disease remain insufficiently studied. The purpose of our study is to analyze the possibility of using the level of ghrelin in blood plasma as a biomarker of non-motor symptoms and sleep disturbances in Parkinson's disease depending on circadian rhythms. We examined 64 patients with Parkinson's disease registered at the Center for Parkinson's Disease and Other Neurodegenerative Diseases, Department of Nervous Diseases, Poltava State Medical University, and 30 patients without signs of neurodegenerative disease. The diagnosis was established according to the criteria of the World Brain Bank of Great Britain. Non-motor manifestations were studied according to the results of the non-motor symptom assessment scale, the severity of sleep disorders was assessed according to the sleep scale at Parkinson's disease. Results. In the course of the study, a decrease in the level of ghrelin in the blood plasma and the connection of the ghrelin content with sleep and digestive system disorders in patients with Parkinson's disease were established. patients, which is consistent with other studies. Ghrelin stimulates motility and emptying of the stomach, as well as motility of the small and large intestines. This indicates the probable role of ghrelin in the pathophysiology of diseases of the digestive system at Parkinson's disease. Conclusions. The level of plasma ghrelin in patients with Parkinson's disease and its diurnal fluctuations can be considered as a potential biomarker of non-motor symptoms and their fluctuations due to its links with sleep disorders and circadian rhythm.

Downloads

Download data is not yet available.

Author Biographies

Kateryna Tarianyk, Poltava State Medical University

PhD, Associate Professor of department of Neurology Poltava State Medical University, Shevchenko Street, 23, Poltava, Ukraine, 36023

Nataliya Lytvynenko , Poltava State Medical University

PhD, Associate Professor of department of Neurology Poltava State Medical University, Shevchenko Street, 23, Poltava, Ukraine, 36023

Halyna Silenko , Poltava State Medical University

PhD, Associate Professor of department of Neurology Poltava State Medical University, Shevchenko Street, 23, Poltava, Ukraine, 36023

Olena Palenka , Poltava State Medical University

Assistant of department of Neurology Poltava State Medical University, Shevchenko Street, 23, Poltava, Ukraine, 36023

References

Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson’s disease (recent update). Neurochem Int 2013;63:201–29. DOI: https://doi.org/10.1016/j.neuint.2013.06.005

Shkodina AD, Tarianyk KA, Boiko DI, Zehravi M, Akter S, Md. Ashraf G, et al. Cognitive and affective disturbances in patients with Parkinson’s disease: Perspectives for classifying of motor/neuropsychiatric subtypes. Neurosci Lett 2022;781:136675. DOI: https://doi.org/10.1016/j.neulet.2022.136675

Skrypnikov AM, Zhyvotovska LV, Herasymenko LO, Boiko DI, Bodnar LA. Alexithymia in healthy people and its role in development of different disorders. Med Ecol Probl 2019;23:30–3. DOI: https://doi.org/10.31718/mep.2019.23.1-2.07

Davies JS. Ghrelin mediated hippocampal neurogenesis, 2022, p. 337–67. https://doi.org/10.1016/bs.vh.2021.12.003

Bayliss JA, Andrews ZB. Ghrelin is neuroprotective in Parkinson’s disease: molecular mechanisms of metabolic neuroprotection. Ther Adv Endocrinol Metab 2013;4:25–36. DOI: https://doi.org/10.1177/2042018813479645

Pietraszko W, Furgala A, Gorecka-Mazur A, Kwinta B, Kaszuba-Zwoinska J, Polak J, et al. Assessments of plasma acyl-ghrelin levels in Parkinson’s disease patients treated with deep brain stimulation. Peptides 2020;128:170299. DOI: https://doi.org/10.1016/j.peptides.2020.170299

Unger MM, Möller JC, Mankel K, Eggert KM, Bohne K, Bodden M, et al. Postprandial ghrelin response is reduced in patients with Parkinson’s disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson’s disease? J Neurol 2011;258:982–90. DOI: https://doi.org/10.1007/s00415-010-5864-1

Tarianyk KA. Rol hormonu holodu v rehuliatsii kharchovoi povedinky patsiientiv iz khvoroboiu Parkinsona. Ukrainskyi nevrolohichnyi zhurnal 2021;1-2:25-29. DOI: https://doi.org/10.30978/UNJ2021-1-2-25.

Sakata I, Takemi S. Ghrelin-cell physiology and role in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2021;28:238–42. DOI: https://doi.org/10.1097/MED.0000000000000610

El-Salhy. Ghrelin in gastrointestinal diseases and disorders: A possible role in the pathophysiology and clinical implications (Review). Int J Mol Med 2009;24. DOI: https://doi.org/10.3892/ijmm_00000285.

Tarianyk KA, Lytvynenko N V., Shkodina AD, Kaidashev IP. The role of circadian regulation of ghrelin levels in Parkinson’s disease (literature review). Wiadomości Lek 2021;74:1750–3. DOI: https://doi.org/10.36740/WLek202107132

Morin V, Hozer F, Costemale-Lacoste J-F. The effects of ghrelin on sleep, appetite, and memory, and its possible role in depression: A review of the literature. Encephale 2018;44:256–63. DOI: https://doi.org/10.1016/j.encep.2017.10.012